WallStreetZenWallStreetZen

NASDAQ: PACB
Pacific Biosciences Of California Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

PACB past revenue growth

How has PACB's revenue growth performed historically?
Company
56.29%
Industry
9.34%
Market
17.33%
PACB's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PACB's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PACB's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

PACB earnings and revenue history

Current Revenue
$200.5M
Current Earnings
-$306.7M
Current Profit Margin
-153%

PACB Return on Equity

Current Company
-43.8%
Current Industry
10.5%
Current Market
188%
PACB's Return on Equity (-43.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when PACB announces earnings.

PACB Return on Assets

Current Company
-16.6%
Current Industry
5.3%
PACB is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

PACB Return on Capital Employed

Current Company
-18.4%
Current Industry
8.3%
PACB's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PACB vs Medical Device Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
PACB$200.52M-$277.28M-$306.74M+20.59%N/A
MXCT$41.29M-$33.36M-$37.92M+17.55%N/A
NPCE$65.42M-$22.83M-$32.96M+15.33%N/A
SRDX$138.20M$22.74M$5.52M+9.81%-5.06%
ANIK$166.66M-$71.19M-$82.67M+9.56%N/A
View Top Medical Device Stocks

PACB earnings dates

Next earnings date
Apr 30, 2024

Pacific Biosciences Of California Earnings & Revenue FAQ

What were PACB's earnings last quarter?

On Invalid Date, Pacific Biosciences Of California (NASDAQ: PACB) reported Q4 2023 earnings per share (EPS) of -$0.31, up 16.22% year over year. Total Pacific Biosciences Of California earnings for the quarter were -$82.02 million. In the same quarter last year, Pacific Biosciences Of California's earnings per share (EPS) was -$0.37.

If you're new to stock investing, here's how to buy Pacific Biosciences Of California stock.

What was PACB's earnings growth in the past year?

As of Q2 2024, Pacific Biosciences Of California's earnings has grown year over year. Pacific Biosciences Of California's earnings in the past year totalled -$306.74 million.

What is PACB's earnings date?

Pacific Biosciences Of California's earnings date is Invalid Date. Add PACB to your watchlist to be reminded of PACB's next earnings announcement.

What was PACB's revenue last quarter?

On Invalid Date, Pacific Biosciences Of California (NASDAQ: PACB) reported Q4 2023 revenue of $58.36 million up 113.35% year over year. In the same quarter last year, Pacific Biosciences Of California's revenue was $27.35 million.

What was PACB's revenue growth in the past year?

As of Q2 2024, Pacific Biosciences Of California's revenue has grown 56.29% year over year. This is 46.95 percentage points higher than the US Medical Devices industry revenue growth rate of 9.34%. Pacific Biosciences Of California's revenue in the past year totalled $200.52 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.